1,515 Shares in Agilent Technologies, Inc. (NYSE:A) Bought by Waterfront Wealth Inc.

Waterfront Wealth Inc. purchased a new stake in Agilent Technologies, Inc. (NYSE:A) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,515 shares of the medical research company’s stock, valued at approximately $204,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. McAdam LLC boosted its position in Agilent Technologies by 3.1% during the third quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 77 shares during the last quarter. Brown Brothers Harriman & Co. lifted its stake in Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 77 shares during the last quarter. Rovin Capital UT ADV lifted its stake in Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares during the last quarter. Integrated Advisors Network LLC increased its position in Agilent Technologies by 2.5% during the third quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock worth $532,000 after buying an additional 86 shares during the last quarter. Finally, Ascent Group LLC raised its stake in Agilent Technologies by 4.1% in the third quarter. Ascent Group LLC now owns 2,209 shares of the medical research company’s stock valued at $328,000 after buying an additional 87 shares during the period. 87.42% of the stock is owned by institutional investors and hedge funds.

Agilent Technologies Trading Down 1.1 %

Shares of A stock opened at $135.33 on Friday. The stock has a market cap of $38.61 billion, a P/E ratio of 30.62, a price-to-earnings-growth ratio of 3.71 and a beta of 1.07. Agilent Technologies, Inc. has a 1 year low of $124.16 and a 1 year high of $155.35. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The stock has a 50 day simple moving average of $140.97 and a 200 day simple moving average of $139.29.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the prior year, the company posted $1.38 EPS. The company’s revenue was up .8% compared to the same quarter last year. On average, research analysts predict that Agilent Technologies, Inc. will post 5.56 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be issued a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.73%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.40%.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the sale, the chief executive officer now owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their target price on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a research note on Tuesday, November 26th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Citigroup increased their price objective on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a research report on Thursday, December 19th. Bank of America reduced their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, Sanford C. Bernstein lowered their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $144.38.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.